← Back to 1cP-AL-LAD

1cP-AL-LAD Stats & Data

Psychedelic Research-chemical

NPS DataHub

MW417.55

FormulaC26H31N3O2

SMILESC=CCN1CC(C(=O)N(CC)CC)C=C2C1Cc1cn(C(=O)C3CC3)c3cccc2c13

InChIKeyVSABTUDYQCMWKE-UHFFFAOYSA-N

Ergolines; 2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene

Chemical Class Lysergamide

Psychoactive Class Psychedelic

Half-Life Unknown in humans. By analogy to other 1‑acyl lysergamides, parent is likely deacylated in vivo; treat total pharmacodynamic course as AL‑LAD‑like rather than relying on numeric half‑life.

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

Other

prodrug of AL-LAD

History & Culture

1cP-AL-LAD is a novel lysergamide that emerged as part of the designer drug market in the early 2020s. The compound is believed to have been first synthesized around 2020 or 2021, reportedly by chemists who were also developing other novel lysergamides during the same period, including compounds such as 1cP-MiPLA. However, the specific origins and identity of those responsible for its initial synthesis remain unverified. The substance was first officially identified by authorities in France in June 2021, marking its entry into forensic and regulatory awareness. Since then, it has circulated primarily through online grey market vendors as a research chemical, following a similar distribution pattern to other novel lysergamides that emerged during this era.

Effect Profile

Curated + 5 Reports

Psychedelic 7.4

Strong visuals and auditory effects with moderate body load, mild headspace

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Based on reports from:

Erowid Experience Reports PsychonautWiki 1cP-AL-LAD

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Unknown in humans. By analogy to other 1‑acyl lysergamides, parent is likely deacylated in vivo; treat total pharmacodynamic course as AL‑LAD‑like rather than relying on numeric half‑life.

Addiction Potential

Low. Like other lysergamides, rapid acute tolerance and minimal compulsive redosing. Physical dependence not expected; psychological habituation possible with frequent use.

Tolerance Decay

Full tolerance 6h Half tolerance 7d Baseline ~14d

Estimates reflect classic psychedelic cross‑tolerance behavior; based on TripSit/community consensus for LSD. Avoid re‑dosing same day; it lengthens duration more than intensity.

Cross-Tolerances

LSD

80% ●●○

AL-LAD

80% ●●○

ETH-LAD

60% ●○○

Experience Report Analysis

Erowid

5 Reports

2021–2025 Date Range

5 With Age Data

8 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 5 experience reports (5 Erowid)

5 Reports

8 Effects Detected

5 Positive

1 Adverse

2 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 5

Color Enhancement 100.0% 70%

Focus Enhancement 100.0% 70%

Stimulation 80.0% 70%

Tactile Enhancement 80.0% 70%

Music Enhancement 60.0% 70%

Adverse Effects 1

Anxiety 80.0% 70%

Form / Preparation

Most common forms and preparations reported

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Austria	Gray area	Not explicitly scheduled but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD. Legal status depends on prosecution interpretation.
Germany	Illegal	Became a controlled substance in July 2021. Possession, production, and distribution are prohibited under amended narcotics legislation.
Switzerland	Controlled (Verzeichnis E)	Regulated as a defined derivative of lysergic acid under Verzeichnis E point 263 of the Swiss narcotics legislation. An exemption exists for legitimate scientific or industrial purposes.
United States	Unscheduled	Not specifically scheduled under the Controlled Substances Act. However, as a structural analogue of LSD, it may be prosecuted under the Federal Analogue Act when sold or possessed with intent for human consumption.

Harm Reduction

drugs.wiki

Evidence base and reasoning for harm reduction updates: (1) Prodrug assumption: 1‑acyl lysergamides (e.g., 1cP‑LSD) hydrolyze to LSD in vitro and behave as prodrugs in animals; by close structural analogy, 1cP‑AL‑LAD is presumed to deacylate to AL‑LAD in vivo, but direct human PK for 1cP‑AL‑LAD is not published. Treat as a potent AL‑LAD source and avoid over‑dosing. TripSit and community reports support AL‑LAD‑like durations and effects. [Support: TripSit LSD page; Bluelight AL‑LAD/1cP‑AL‑LAD threads; Erowid reports.]

(2) Dose variability and mislabeling: Community LCMS work has shown some blotter series contaminated or under‑dosed; visual appearance/printing is not proof of identity. Use Ehrlich/Weil reagents to confirm an indole, and prefer lab drug‑checking where available. Volumetric dosing increases accuracy when cutting tabs. [Support: Reddit LCMS thread; drug checking services availability.]

(3) Interactions: TripSit’s drug‑combination guidance flags LSD with lithium and tramadol as hazardous; SSRIs generally reduce effects; stimulants and MAOIs increase risks. Erowid documents lithium + LSD seizure cases, so lithium is escalated to “dangerous.” [Support: TripSit combo wiki; TripSit LSD page; Erowid LSD & antidepressants page (lithium section).]

(4) Tolerance: Acute tolerance develops rapidly; cross‑tolerance exists with LSD and other classic psychedelics. Waiting 10–14 days restores most sensitivity; re‑dosing the same day extends duration more than intensity. [Support: TripSit LSD/tolerance content.]

(5) Duration: User timelines and TiHKAL‑derived AL‑LAD summaries indicate a somewhat shorter and punchier course than LSD, with 6–9 h active for many; after‑effects can still disturb sleep. [Support: Bluelight AL‑LAD threads citing TiHKAL; Erowid/Bluelight reports.]

(6) Storage: As with other lysergamides, minimize heat, light, oxygen, and moisture; foil + airtight + desiccant in a cool/dark place improves stability. Allow cold‑stored blotter to reach room temp before opening to avoid condensation. [Support: TripSit LSD page storage guidance.]

(7) Set, setting, and sitters: Avoid if unstable mood or recent mania/hypomania; have a trusted sober sitter at higher doses. Keep an anxiolytic (e.g., low‑dose benzodiazepine) available for emergencies only; mixing with alcohol or opioids increases respiratory/sedation risks. Start low when combining with cannabis or dissociatives due to potentiation.

(8) ROA caution: Intranasal use of lysergamides lacks robust data and may irritate mucosa; sublingual/oral routes are better characterized and preferred for harm reduction.